Table 1.
Demographic characteristics
| Whole cohort (n=56) | Low-dose COH04S1 group*(n=18) | Medium-dose COH04S1 group*(n=9) | High-dose COH04S1 group*(n=10) | Placebo group (n=5) | Low-dose COH04S1 plus placebo group (n=14) | ||
|---|---|---|---|---|---|---|---|
| Age, years | 41 (21–55) | 46 (26–51) | 39 (28–55) | 32 (26–54) | 35 (24–46) | 40 (21–55) | |
| Gender | |||||||
| Female | 31 (55%) | 10 (56%) | 6 (67%) | 6 (60%) | 2 (40%) | 7 (50%) | |
| Male | 25 (45%) | 8 (44%) | 3 (33%) | 4 (40%) | 3 (60%) | 7 (50%) | |
| Body-mass index, kg/m2 | 25·0 (19·4–30·0) | 25·3 (19·7–30·0) | 25·8 (20·2–30·0) | 22·4 (19·4–29·9) | 21·3 (21·1–28·5) | 25·0 (22·2–29·9) | |
| Race | |||||||
| Asian | 10 (18%) | 2 (11%) | 1 (11%) | 1 (10%) | 2 (40%) | 4 (29%) | |
| Non-disclosed | 2 (4%) | 0 | 1 (11%) | 0 | 0 | 1 (7%) | |
| Unknown | 8 (14%) | 1 (5·6%) | 3 (33%) | 4 (40%) | 0 | 0 | |
| White | 36 (64%) | 15 (83%) | 4 (44%) | 5 (50%) | 3 (60%) | 9 (64%) | |
| Ethnicity | |||||||
| Hispanic | 13 (23%) | 4 (22%) | 4 (44%) | 3 (30%) | 0 | 2 (14%) | |
| Non-Hispanic | 40 (71%) | 14 (78%) | 5 (56%) | 5 (50%) | 5 (100%) | 11 (79%) | |
| Non-disclosed | 1 (2%) | 0 | 0 | 0 | 0 | 1 (7%) | |
| Unknown | 2 (4%) | 0 | 0 | 2 (20%) | 0 | 0 | |
Data are median (range) or n (%).
*
Includes participants from the open-label and two randomised dose expansions cohorts.